{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T11:04:21Z","timestamp":1755601461760},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T00:00:00Z","timestamp":1617667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T00:00:00Z","timestamp":1617667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s00105-021-04801-9","type":"journal-article","created":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T12:02:26Z","timestamp":1617710546000},"page":"393-402","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Neue Botulinumtoxine in der \u00e4sthetischen Dermatologie"],"prefix":"10.1007","volume":"72","author":[{"given":"A.","family":"Patil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kassir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Wollina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Goldust","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,6]]},"reference":[{"key":"4801_CR1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2147\/CIA.S9338","volume":"5","author":"K De Boulle","year":"2010","unstructured":"De Boulle\u00a0K, Fagien\u00a0S, Sommer\u00a0B, Glogau\u00a0R (2010) Treating glabellar lines with botulinum toxin type A\u2011hemagglutinin complex: a review of the science, the clinical data, and patient satisfaction. Clin Interv Aging 5:101\u2013118","journal-title":"Clin Interv Aging"},{"key":"4801_CR2","first-page":"48","volume":"17","author":"LG Wiest","year":"2009","unstructured":"Wiest\u00a0LG (2009) An overview of the cosmetic treatment of facial muscles with a\u00a0new botulinum toxin. Acta Dermatovenerol Croat 17:48\u201353","journal-title":"Acta Dermatovenerol Croat"},{"key":"4801_CR3","doi-asserted-by":"publisher","first-page":"258","DOI":"10.7861\/clinmedicine.4-3-258","volume":"4","author":"PT Ting","year":"2004","unstructured":"Ting\u00a0PT, Freiman\u00a0A (2004) The story of Clostridium botulinum: from food poisoning to Botox. Clin Med 4:258\u2013261","journal-title":"Clin Med"},{"key":"4801_CR4","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/dsu.12147","volume":"39","author":"A Carruthers","year":"2013","unstructured":"Carruthers\u00a0A, Kane\u00a0MAC, Flynn\u00a0TC et al (2013) The convergence of medicine and neurotoxins: a\u00a0focus on botulinum toxin type a\u00a0and its application in aesthetic medicine \u2013 a\u00a0global, evidence-based botulinum toxin consensus education initiative part I: Botulinum toxin in clinical and cosmetic practice. Dermatol Surg 39:493\u2013509","journal-title":"Dermatol Surg"},{"key":"4801_CR5","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1473-2165.2010.00545.x","volume":"10","author":"A Feily","year":"2011","unstructured":"Feily\u00a0A, Fallahi\u00a0H, Zandian\u00a0D, Kalantar\u00a0H (2011) A succinct review of botulinum toxin in dermatology; update of cosmetic and noncosmetic use. J\u00a0Cosmetic Dermatol 10:58\u201367","journal-title":"J Cosmetic Dermatol"},{"issue":"3 Suppl","key":"4801_CR6","first-page":"S31","volume":"9","author":"Hexsel D, Spencer JM, Woolery-Lloyd H, Gilbert E (","year":"2010","unstructured":"Hexsel D, Spencer JM, Woolery-Lloyd H, Gilbert E ( (2010) Practical applications of a\u00a0new botulinum toxin. J\u00a0Drugs Dermatol 9(3 Suppl):S31\u2013S37","journal-title":"J Drugs Dermatol"},{"key":"4801_CR7","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3109\/14764170903480013","volume":"12","author":"NJ Lowe","year":"2010","unstructured":"Lowe\u00a0NJ, Shah\u00a0A, Lowe\u00a0PL, Patnaik\u00a0R (2010) Dosing, efficacy and safety plus the use of computerized photography for botulinum toxins type A for upper facial lines. J\u00a0Cosmet Laser Ther 12:106\u2013111","journal-title":"J Cosmet Laser Ther"},{"key":"4801_CR8","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/sj.bdj.2018.126","volume":"224","author":"G Wright","year":"2018","unstructured":"Wright\u00a0G, Lax\u00a0A, Mehta\u00a0SB (2018) A review of the longevity of effect of botulinum toxin in wrinkle treatments. Br Dent\u00a0J 224:255\u2013260","journal-title":"Br Dent J"},{"key":"4801_CR9","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.2165\/11599840-000000000-00000","volume":"26","author":"R Benecke","year":"2012","unstructured":"Benecke\u00a0R (2012) Clinical relevance of botulinum toxin immunogenicity. BioDrugs 26:e1\u2013e9","journal-title":"BioDrugs"},{"key":"4801_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4103\/0974-2077.41148","volume":"1","author":"U Wollina","year":"2008","unstructured":"Wollina\u00a0U (2008) Botulinum toxin: non-cosmetic indications and possible mechanisms of action. J\u00a0Cutan Aesthet Surg 1:3\u20136","journal-title":"J Cutan Aesthet Surg"},{"key":"4801_CR11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.asj.2008.03.006","volume":"28","author":"SR Freeman","year":"2008","unstructured":"Freeman\u00a0SR, Cohen\u00a0JL (2008) New neurotoxins on the horizon. Aesthet Surg\u00a0J 28:325\u2013330","journal-title":"Aesthet Surg J"},{"key":"4801_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1055\/s-0035-1571215","volume":"36","author":"R Kumar","year":"2016","unstructured":"Kumar\u00a0R, Dhaliwal\u00a0HP, Kukreja\u00a0RV, Singh\u00a0BR (2016) The botulinum toxin as a\u00a0therapeutic agent: molecular structure and mechanism of action in motor and sensory systems. Semin Neurol 36:10\u201319","journal-title":"Semin Neurol"},{"key":"4801_CR13","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.ophtha.2005.03.021","volume":"112","author":"SA Kaltreider","year":"2005","unstructured":"Kaltreider\u00a0SA, Kennedy\u00a0RH, Woog\u00a0JJ et\u00a0al (2005) Cosmetic oculofacial applications of botulinum toxin a\u00a0report by the American Academy of Ophthalmology. Ophthalmology 112:1159\u20131167","journal-title":"Ophthalmology"},{"key":"4801_CR14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s13555-012-0014-6","volume":"2","author":"N Lowe","year":"2012","unstructured":"Lowe\u00a0N, Lowe\u00a0P (2012) Botulinum toxins for facial lines: a concise review. Dermatol Ther 2:14","journal-title":"Dermatol Ther"},{"key":"4801_CR15","first-page":"1065","volume":"9","author":"G Sattler","year":"2010","unstructured":"Sattler\u00a0G (2010) Current and future botulinum neurotoxin type a\u00a0preparations in aesthetics: a literature review. J\u00a0Drugs Dermatol 9:1065\u20131071","journal-title":"J Drugs Dermatol"},{"issue":"Suppl 1","key":"4801_CR16","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1093\/asj\/sjw285","volume":"37","author":"MA Kane","year":"2017","unstructured":"Kane\u00a0MA, Monheit\u00a0G (2017) The practical use of abobotulinumtoxin A in aesthetics. Aesthet Surg\u00a0J 37(Suppl 1):S12\u2013S19","journal-title":"Aesthet Surg J"},{"key":"4801_CR17","first-page":"31","volume":"7","author":"JJ Walker","year":"2014","unstructured":"Walker\u00a0JJ, Dayan\u00a0SH (2014) Comparison and overview of currently available neurotoxins. J\u00a0Clin Aesthet Dermatol 7:31\u201339","journal-title":"J Clin Aesthet Dermatol"},{"key":"4801_CR18","doi-asserted-by":"publisher","first-page":"e2627","DOI":"10.1097\/GOX.0000000000002627","volume":"8","author":"J-Y Park","year":"2020","unstructured":"Park\u00a0J\u2011Y, Sunga\u00a0O, Wanitphakdeedecha\u00a0R, Frevert\u00a0J (2020) Neurotoxin impurities: a review of threats to efficacy. Plast Reconstr Surg Glob Open 8:e2627","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"4801_CR19","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1067\/mjd.2002.121356","volume":"46","author":"JA Carruthers","year":"2002","unstructured":"Carruthers\u00a0JA, Lowe\u00a0NJ, Menter\u00a0MA et al (2002) A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J\u00a0Am Acad Dermatol 46:840\u2013849","journal-title":"J Am Acad Dermatol"},{"key":"4801_CR20","first-page":"1","volume":"7","author":"A Carruthers","year":"2004","unstructured":"Carruthers\u00a0A, Carruthers\u00a0J, Lowe\u00a0NJ et al (2004) One-year, randomized, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar lines. J\u00a0Clin Res 7:1\u201320","journal-title":"J Clin Res"},{"key":"4801_CR21","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1097\/DSS.0000000000000704","volume":"42","author":"A Carruthers","year":"2016","unstructured":"Carruthers\u00a0A, Carruthers\u00a0J, Fagien\u00a0S et\u00a0al (2016) Repeated onabotulinumtoxin a\u00a0treatment of glabellar lines at rest over three treatment cycles. Dermatol Surg 42:1094\u20131101","journal-title":"Dermatol Surg"},{"key":"4801_CR22","doi-asserted-by":"publisher","first-page":"709","DOI":"10.2165\/00128071-200304100-00005","volume":"4","author":"JE Frampton","year":"2003","unstructured":"Frampton\u00a0JE, Easthope\u00a0SE (2003) Botulinum toxin A (Botox Cosmetic): a\u00a0review of its use in the treatment of glabellar frown lines. Am J Clin Dermatol 4:709\u2013725","journal-title":"Am J Clin Dermatol"},{"key":"4801_CR23","unstructured":"Botox PI. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/103000s5236lbl.pdf. Zugegriffen: 27. Dez. 2020"},{"key":"4801_CR24","first-page":"1","volume":"13","author":"A Carruthers","year":"2008","unstructured":"Carruthers\u00a0A, Carruthers\u00a0J (2008) Botulinum toxin products overview. Skin Therapy Lett 13:1\u20134","journal-title":"Skin Therapy Lett"},{"key":"4801_CR25","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1093\/asj\/sjw282","volume":"37","author":"M Nestor","year":"2017","unstructured":"Nestor\u00a0M, Ablon\u00a0G, Pickett\u00a0A (2017) Key parameters for the use of abobotulinumtoxin A in aesthetics: onset and duration. Aesthet Surg\u00a0J 37:S20\u2013S31","journal-title":"Aesthet Surg J"},{"key":"4801_CR26","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1097\/PRS.0b013e3181b5641b","volume":"124","author":"MAC Kane","year":"2009","unstructured":"Kane\u00a0MAC, Brandt\u00a0F, Rohrich\u00a0RJ et al (2009) Evaluation of variable-dose treatment with a\u00a0new U.S. Botulinum Toxin Type A (Dysport) for correction of moderate to severe glabellar lines: results from a\u00a0phase III, randomized, double-blind, placebo-controlled study. Plast Reconstr Surg 124:1619\u20131629","journal-title":"Plast Reconstr Surg"},{"key":"4801_CR27","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1111\/j.1524-4725.2009.01235.x","volume":"35","author":"F Brandt","year":"2009","unstructured":"Brandt\u00a0F, Swanson\u00a0N, Baumann\u00a0L, Huber\u00a0B (2009) Randomized, placebo-controlled study of a\u00a0new botulinum toxin type a\u00a0for treatment of glabellar lines: efficacy and safety. Dermatol Surg 35:1893\u20131901","journal-title":"Dermatol Surg"},{"issue":"Suppl 6","key":"4801_CR28","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/j.asj.2009.09.012","volume":"29","author":"L Baumann","year":"2009","unstructured":"Baumann\u00a0L, Brandt\u00a0FS, Kane\u00a0MAC, Donofrio\u00a0LM (2009) An analysis of efficacy data from four phase III studies of botulinum neurotoxin type A\u2011ABO for the treatment of glabellar lines. Aesthet Surg\u00a0J 29(Suppl 6):S57\u2013S65","journal-title":"Aesthet Surg J"},{"issue":"Suppl 6","key":"4801_CR29","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/j.asj.2009.09.003","volume":"29","author":"JL Cohen","year":"2009","unstructured":"Cohen\u00a0JL, Schlessinger\u00a0J, Cox\u00a0SE, Lin\u00a0X, Reloxin Investigational Group (2009) An analysis of the long-term safety data of repeat administrations of botulinum neurotoxin type A\u2011ABO for the treatment of glabellar lines. Aesthet Surg\u00a0J 29(Suppl 6):S43\u2013S49","journal-title":"Aesthet Surg J"},{"issue":"Suppl 6","key":"4801_CR30","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1016\/j.asj.2009.09.010","volume":"29","author":"M Rubin","year":"2009","unstructured":"Rubin\u00a0M, Dover\u00a0J, Mass\u00a0C, Nestor\u00a0M (2009) An analysis of safety data from five phase III clinical trials on the use of botulinum neurotoxin type A\u2011ABO for the treatment of glabellar lines. Aesthet Surg\u00a0J 29(Suppl 6):S50\u2013S56","journal-title":"Aesthet Surg J"},{"issue":"Suppl 6","key":"4801_CR31","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1016\/j.asj.2009.09.009","volume":"29","author":"I Lawrence","year":"2009","unstructured":"Lawrence\u00a0I, Moy\u00a0R (2009) An evaluation of neutralizing antibody induction during treatment of glabellar lines with a\u00a0new US formulation of botulinum neurotoxin type A. Aesthet Surg\u00a0J 29(Suppl 6):S66\u2013S71","journal-title":"Aesthet Surg J"},{"key":"4801_CR32","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1007\/s00266-018-1200-4","volume":"42","author":"E Gubanova","year":"2018","unstructured":"Gubanova\u00a0E, Tabet\u00a0MH, Bergerova\u00a0Y et al (2018) Assessment of subject and physician satisfaction after long-term treatment of glabellar lines with abobotulinumtoxinA (Dysport\u00a0\u00ae\/Azzalure\u00a0\u00ae): Primary results of the APPEAL noninterventional study. Aesthetic Plast Surg 42:1672\u20131680","journal-title":"Aesthetic Plast Surg"},{"key":"4801_CR33","unstructured":"Dysport. PI. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/125274s107lbl.pdf. Zugegriffen: 27. Dez. 2020"},{"key":"4801_CR34","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1093\/asj\/sjx010","volume":"37","author":"JL Cohen","year":"2017","unstructured":"Cohen\u00a0JL, Scuderi\u00a0N (2017) Safety and patient satisfaction of abobotulinumtoxina for aesthetic use: a\u00a0systematic review. Aesthet Surg\u00a0J 37:S32\u2013S44","journal-title":"Aesthet Surg J"},{"key":"4801_CR35","first-page":"70","volume":"3","author":"A Redaelli","year":"2017","unstructured":"Redaelli\u00a0A, Saromytskaya\u00a0A, Roland Payne\u00a0C et\u00a0al (2017) International experts recommendations on the use of AboBotulinum Toxin A (AboTA) for facial rejuvenation and primary hyperhidrosis. Cosmet Med Int 3:70\u201380","journal-title":"Cosmet Med Int"},{"key":"4801_CR36","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1097\/PRS.0000000000001032","volume":"135","author":"JE Kim","year":"2015","unstructured":"Kim\u00a0JE, Song\u00a0EJ, Choi\u00a0GS et al (2015) The efficacy and safety of liquid-type botulinum toxin type A for the management of moderate to severe glabellar frown lines. Plast Reconstr Surg 135:732\u2013741","journal-title":"Plast Reconstr Surg"},{"key":"4801_CR37","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/asj\/sjz003","volume":"40","author":"B Ascher","year":"2020","unstructured":"Ascher\u00a0B, Rzany\u00a0B, Kestemont\u00a0P et al (2020) Liquid formulation of abobotulinumtoxin A: A 6\u2011month, phase 3, double-blind, randomized, placebo-controlled study of a\u00a0single treatment, ready-to-use toxin for moderate-to-severe glabellar lines. Aesthet Surg\u00a0J 40:93\u2013104","journal-title":"Aesthet Surg J"},{"key":"4801_CR38","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1093\/asj\/sjz248","volume":"40","author":"B Ascher","year":"2020","unstructured":"Ascher\u00a0B, Rzany\u00a0B, Kestemont\u00a0P et al (2020) significantly increased patient satisfaction following liquid formulation abobotulinumtoxin A treatment in glabellar lines: face\u2011q outcomes from a\u00a0phase 3 clinical trial. Aesthet Surg\u00a0J 40:1000\u20131008","journal-title":"Aesthet Surg J"},{"issue":"Suppl 2","key":"4801_CR39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1468-1331.2009.02879.x","volume":"16","author":"J Frevert","year":"2009","unstructured":"Frevert\u00a0J (2009) Xeomin: an innovative new botulinum toxin type A. Eur J Neurol 16(Suppl 2):11\u201313","journal-title":"Eur J Neurol"},{"key":"4801_CR40","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/toxins8010004","volume":"8","author":"H-M Oh","year":"2015","unstructured":"Oh\u00a0H\u2011M, Park\u00a0JH, Song\u00a0DH, Chung\u00a0ME (2015) Efficacy and safety of a\u00a0new botulinum toxin type a\u00a0free of complexing proteins. Toxins 8:4","journal-title":"Toxins"},{"key":"4801_CR41","unstructured":"Xeomin. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125360s073lbl.pdf. Zugegriffen: 27. Dez. 2020"},{"key":"4801_CR42","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1097\/DSS.0000000000000450","volume":"41","author":"M Kerscher","year":"2015","unstructured":"Kerscher\u00a0M, Rzany\u00a0B, Prager\u00a0W et al (2015) efficacy and safety of incobotulinumtoxin A in the treatment of upper facial lines: results from a\u00a0randomized, double-blind, placebo-controlled, phase III study. Dermatol Surg 41:1149\u20131157","journal-title":"Dermatol Surg"},{"key":"4801_CR43","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1097\/DSS.0000000000001076","volume":"43","author":"W Prager","year":"2017","unstructured":"Prager\u00a0W, Nogueira Teixeira\u00a0D, Leventhal\u00a0PS (2017) Incobotulinumtoxin A for aesthetic indications: a\u00a0systematic review of prospective comparative trials. Dermatol Surg 43:959\u2013966","journal-title":"Dermatol Surg"},{"key":"4801_CR44","doi-asserted-by":"publisher","first-page":"S235","DOI":"10.1097\/DSS.0000000000001295","volume":"43","author":"DH Jones","year":"2017","unstructured":"Jones\u00a0DH, Kerscher\u00a0M, Geister\u00a0T, Hast\u00a0MA, Weissenberger\u00a0P (2017) Efficacy of incobotulinumtoxin A for the treatment of glabellar frown lines in male subjects: post-hoc analyses from randomized, double-blind pivotal studies. Dermatol Surg 43:S235\u2013S241","journal-title":"Dermatol Surg"},{"key":"4801_CR45","first-page":"E53","volume":"12","author":"YY Chao","year":"2019","unstructured":"Chao\u00a0YY, Tseng\u00a0FW, Yang\u00a0YL et al (2019) Incobotulinumtoxin A for the treatment of glabellar frown lines: a\u00a0prospective, multicenter, single-arm study in Taiwan. J\u00a0Clin Aesthet Dermatol 12:E53\u2013E57","journal-title":"J Clin Aesthet Dermatol"},{"key":"4801_CR46","doi-asserted-by":"publisher","first-page":"461","DOI":"10.36849\/JDD.2020.5013","volume":"19","author":"T Fischer","year":"2020","unstructured":"Fischer\u00a0T, Sattler\u00a0G, Prager\u00a0W et al (2020) Safety, tolerability, and efficacy of repeat-dose injections of incobotulinumtoxin A in the treatment of upper facial lines: results from a\u00a0prospective, open-label, phase III study. J\u00a0Drugs Dermatol 19:461\u2013469","journal-title":"J Drugs Dermatol"},{"key":"4801_CR47","doi-asserted-by":"publisher","first-page":"985","DOI":"10.36849\/JDD.2020.5454","volume":"19","author":"M Kerscher","year":"2020","unstructured":"Kerscher\u00a0M, Fabi\u00a0S, Fischer\u00a0T et al (2020) Incobotulinumtoxin A demonstrates safety and prolonged duration of effect in a\u00a0dose-ranging study for glabellar lines. J\u00a0Drugs Dermatol 19:985\u2013991","journal-title":"J Drugs Dermatol"},{"key":"4801_CR48","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2147\/CCID.S281901","volume":"14","author":"C de Sanctis Pecora","year":"2021","unstructured":"de Sanctis Pecora\u00a0C, Pinheiro\u00a0MVB, Ventura Ferreira\u00a0K, Jacobino de Barros Nunes\u00a0G, Miot\u00a0HA (2021) The One21 technique: an individualized treatment for glabellar lines based on clinical and anatomical landmarks. Clin Cosmet Investig Dermatol 14:97\u2013105","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"4801_CR49","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/jdv.16997","volume":"35","author":"V Vachiramon","year":"2021","unstructured":"Vachiramon\u00a0V, Subpayasarn\u00a0U, Triyangkulsri\u00a0K, Jurairattanaporn\u00a0N, Rattananukrom\u00a0T (2021) Different injection patterns of incobotulinumtoxinA for crow\u2019s feet: a\u00a0split-face comparative study. J\u00a0Eur Acad Dermatol Venereol 35:256\u2013262","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4801_CR50","doi-asserted-by":"publisher","first-page":"49","DOI":"10.36849\/JDD.5616","volume":"20","author":"JY Park","year":"2021","unstructured":"Park\u00a0JY, Cho\u00a0SI, Hur\u00a0K, Lee\u00a0DH (2021) Intradermal microdroplet injection of diluted incobotulinumtoxin\u2011A for sebum control, face lifting, and pore size improvement. J\u00a0Drugs Dermatol 20:49\u201354","journal-title":"J Drugs Dermatol"},{"key":"4801_CR51","first-page":"58","volume":"1","author":"LM Ferreira","year":"2009","unstructured":"Ferreira\u00a0LM, Filho\u00a0ST, Costa\u00a0RO et\u00a0al (2009) Efficacy and tolerability of a\u00a0new botulinum toxin type a\u00a0for cosmetic treatment of dynamic facial wrinkles: a\u00a0prospective, phase III multicenter study. Surg Cosmet Dermatol 1:58\u201363","journal-title":"Surg Cosmet Dermatol"},{"key":"4801_CR52","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1093\/asj\/sjy207","volume":"39","author":"A da Costa","year":"2019","unstructured":"da Costa\u00a0A, Pereira\u00a0ESP, de Oliveira Pereira\u00a0M et al (2019) Six-month comparative analysis monitoring the progression of the largest diameter of the sweating Inhibition halo of different botulinum toxins type\u2011A. Aesthet Surg\u00a0J 39:993\u20131004","journal-title":"Aesthet Surg J"},{"key":"4801_CR53","unstructured":"FDA 761085Orig1s000 \u2013 FDA. https:\/\/www.accessdata.fda.gov \u203a drugsatfda_docs \u203a nda. Zugegriffen: 15. Jan. 2021"},{"key":"4801_CR54","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1097\/DSS.0000000000001920","volume":"45","author":"HI Cheon","year":"2019","unstructured":"Cheon\u00a0HI, Jung\u00a0N, Won\u00a0CH et al (2019) Efficacy and safety of prabotulinumtoxin A and onabotulinumtoxin A for crow\u2019s feet: a phase 3, multicenter, randomized, double-blind, split-face study. Dermatol Surg 45:1610\u20131619","journal-title":"Dermatol Surg"},{"key":"4801_CR55","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1097\/DSS.0000000000001206","volume":"43","author":"J Carruthers","year":"2017","unstructured":"Carruthers\u00a0J, Solish\u00a0N, Humphrey\u00a0S et al (2017) injectable daxibotulinumtoxin A for the treatment of glabellar lines: a\u00a0phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxina and placebo. Dermatol Surg 43:1321\u20131331","journal-title":"Dermatol Surg"},{"key":"4801_CR56","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/PRS.0000000000006327","volume":"145","author":"JD Carruthers","year":"2020","unstructured":"Carruthers\u00a0JD, Fagien\u00a0S, Joseph\u00a0JH et al (2020) Daxibotulinumtoxin A for injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3\u00a0studies (SAKURA 1 and SAKURA 2). Plast Reconstr Surg 145:45\u201358","journal-title":"Plast Reconstr Surg"},{"key":"4801_CR57","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/DSS.0000000000002531","volume":"47","author":"SG Fabi","year":"2021","unstructured":"Fabi\u00a0SG, Cohen\u00a0JL, Green\u00a0LJ et al (2021) Daxibotulinumtoxin A for injection for the treatment of glabellar lines: efficacy results from sakura 3, a\u00a0large, open-label, phase 3 safety study. Dermatol Surg 47:48\u201354","journal-title":"Dermatol Surg"},{"key":"4801_CR58","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/DSS.0000000000002463","volume":"47","author":"JB Green","year":"2021","unstructured":"Green\u00a0JB, Mariwalla\u00a0K, Coleman\u00a0K et al (2021) A large, open-label, phase 3 safety study of daxibotulinumtoxin A for injection in glabellar lines: a\u00a0focus on safety from the SAKURA 3\u00a0study. Dermatol Surg 47:42\u201346","journal-title":"Dermatol Surg"},{"key":"4801_CR59","unstructured":"Clinical Trial.gov: NCT00752050; NCT00752258; NCT00752297."},{"key":"4801_CR60","unstructured":"Microgen. https:\/\/www.microgen.ru. Zugegriffen: 16. Jan. 2021"},{"key":"4801_CR61","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3341\/kjo.2009.23.3.137","volume":"23","author":"JS Yoon","year":"2009","unstructured":"Yoon\u00a0JS, Kim\u00a0JC, Lee\u00a0SY (2009) Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm. Korean J Ophthalmol 23:137\u2013141","journal-title":"Korean J Ophthalmol"},{"key":"4801_CR62","unstructured":"Clinical Trial.gov: NCT03289169"},{"key":"4801_CR63","unstructured":"Jeong-yeo L (2020) Drug Ministry revokes Meditoxin license. The Korean Herald vom 18. Juni 2020"},{"key":"4801_CR64","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2147\/CCID.S160723","volume":"11","author":"J Frevert","year":"2018","unstructured":"Frevert\u00a0J, Ahn\u00a0KY, Park\u00a0MY, Sunga\u00a0O (2018) Comparison of botulinum neurotoxin type A formulations in Asia. Clin Cosmet Investig Dermatol 11:327\u2013331","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"4801_CR65","doi-asserted-by":"publisher","DOI":"10.1007\/s00266-020-02027-z","author":"S Ahsanuddin","year":"2020","unstructured":"Ahsanuddin\u00a0S, Roy\u00a0S, Nasser\u00a0W et\u00a0al (2020) Adverse events associated with Botox as reported in a\u00a0Food and Drug Administration Database. Aesthetic Plast Surg. https:\/\/doi.org\/10.1007\/s00266-020-02027-z","journal-title":"Aesthetic Plast Surg"},{"key":"4801_CR66","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2165\/00128071-200506030-00001","volume":"6","author":"U Wollina","year":"2005","unstructured":"Wollina\u00a0U, Konrad\u00a0H (2005) Managing adverse events associated with botulinum toxin type A: a\u00a0focus on cosmetic procedures. Am J Clin Dermatol 6:141\u2013150","journal-title":"Am J Clin Dermatol"},{"issue":"S1","key":"4801_CR67","first-page":"1","volume":"11","author":"WG Philipp-Dormston","year":"2013","unstructured":"Philipp-Dormston\u00a0WG, Bergfeld\u00a0D, Sommer\u00a0B, die Onabotulinumtoxin-Konsensusgruppe (2013) Konsensusempfehlungen zur Behandlung mit Onabotulinumtoxin A in der \u00e4sthetischen Medizin. J\u00a0Dtsch Dermatol Ges 11(S1):1\u201342","journal-title":"J Dtsch Dermatol Ges"},{"key":"4801_CR68","doi-asserted-by":"publisher","first-page":"413","DOI":"10.2147\/CCID.S138274","volume":"10","author":"J Anido","year":"2017","unstructured":"Anido\u00a0J, Arenas\u00a0D, Arruabarrena\u00a0C et\u00a0al (2017) Tailored botulinum toxin type A injections in aesthetic medicine: consensus panel recommendations for treating the forehead based on individual facial anatomy and muscle tone. Clin Cosmet Investig Dermatol 10:413\u2013421","journal-title":"Clin Cosmet Investig Dermatol"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-021-04801-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-021-04801-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-021-04801-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T10:16:45Z","timestamp":1620209805000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-021-04801-9"}},"subtitle":["Ein umfassender \u00dcberblick"],"short-title":[],"issued":{"date-parts":[[2021,4,6]]},"references-count":68,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["4801"],"URL":"https:\/\/doi.org\/10.1007\/s00105-021-04801-9","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,6]]},"assertion":[{"value":"3 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0Patil, M.\u00a0Kassir, U.\u00a0Wollina und M.\u00a0Goldust geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}